Association of Androgen Deprivation Therapy With Cardiovascular Death in Patients With Prostate Cancer

JAMA. 2011 Dec 14;306(21):2359-2366, PL Nguyen, Y Je, FAB Schutz, KE Hoffman, JC Hu, A Parekh, JA Beckman, TK Choueiri

TAKE-HOME MESSAGE

Abstract

SUMMARY

OncologySTAT Editorial Team

Androgen deprivation therapy (ADT) is an often-used treatment for prostate cancer, but studies have yielded mixed results regarding the role of ADT and an increased risk of cardiovascular deaths. This highly controversial issue has been the subject of a joint statement by several medical societies and a safety warning by the US Food and Drug Administration. To address this question, this up-to-date meta-analysis from a systematic review of randomized controlled trials was performed to determine whether...

NOT A MEMBER?

Registration is FREE

  • Up-to-date oncology news
  • Journal article summaries
  • Commentaries and interviews
  • Drug and interactions database
  • Chemotherapy regimens
  • Daily e-newsletters

 

About Our Journal Scans

View a list of journals that the OncologySTAT editorial team scans every week in order to bring you the most practice-relevant original research and review articles.

Sign up for our newsletters

Too busy to follow cancer's top stories? Sign-up for 1 or more of our free newsletters -- delivered weekly to your inbox.

Cancer Type

  • Bladder
  • Bone
  • Breast
  • Breast (ER-Positive)
  • CNS/Brain
  • Colon and Rectum
  • Endocrine System
  • Esophagus
  • GYN (Non-Ovary)
  • GYN (Ovary)
  • Head and Neck
  • Hodgkin's Lymphoma
  • Kidney (Renal Cell)
  • Leukemia
  • Liver and Bile Duct
  • Lung
  • Multiple Myeloma
  • Myelodysplastic Syndrome
  • Myeloproliferative Diseases
  • Non-Hodgkin's Lymphoma
  • Pancreas
  • Pediatric Cancers
  • Prostate
  • Rare Cancers
  • Skin
  • Soft-Tissue Sarcoma
  • Stomach
  • Testicle
  • Forgot your password?
    Not a member? Free registration